CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Dual Antiplatelet Therapy Duration: Reconciling the Inconsistencies Haemodynamic-guided management of heart failure (GUIDE-HF): a randomised controlled trial Operator Experience and Outcomes After Left Main Percutaneous Coronary Intervention Coronary artery imaging with intravascular high-frequency ultrasound A Randomized Controlled Trial to Evaluate the Safety and Efficacy of Cardiac Contractility Modulation Usefulness of minimum stent cross sectional area as a predictor of angiographic restenosis after primary percutaneous coronary intervention in acute myocardial infarction (from the HORIZONS-AMI Trial IVUS substudy) Simple Electrocardiographic Measures Improve Sudden Arrhythmic Death Prediction in Coronary Disease Antithrombotic Therapy for Atherosclerotic Cardiovascular Disease Risk Mitigation in Patients With Coronary Artery Disease and Diabetes Mellitus Clinical Impact of Valvular Heart Disease in Elderly Patients Admitted for Acute Coronary Syndrome: Insights From the Elderly-ACS 2 Study Dilated cardiomyopathy: so many cardiomyopathies!

Original Research2014 Jun 15;174(2):299-305.

JOURNAL:Int J Cardiol. Article Link

Contemporary prevalence of pulmonary arterial hypertension in adult congenital heart disease following the updated clinical classification

van Riel AC, Schuuring MJ, Bouma BJ et al. Keywords: adult congenital heart disease; echocardiography; epidemiology; prevalence; pulmonary arterial hypertension

ABSTRACT


BACKGROUND - The aging congenital heart disease (CHD) population is prone to develop a variety of sequelae, including pulmonary arterial hypertension (PAH). Previous prevalence estimates are limited in applicability due to the use of tertiary centers, or database encoding only. We aimed to investigate the contemporary prevalence of PAH in adult CHD patients, using a nationwide population.

 

METHODS - A cross-sectional study was performed, using the population-based Dutch CONgenital CORvitia (CONCOR) registry. All patients born with a systemic-to-pulmonary shunt, thereby at risk of developing PAH, were identified. From this cohort, a random sample was obtained and carefully reviewed.

 

RESULTS - Of 12,624 registered adults with CHD alive in 2011, 5,487 (44%) were at risk of PAH. The random sample consisted of 1,814 patients (mean age 40 ± 15 years) and 135 PAH cases were observed. PAH prevalence in patients born with a systemic-to-pulmonary shunt was 7.4%. The prevalence of PAH after corrective cardiac surgery was remarkably high (5.7%). Furthermore, PAH prevalence increased with age, from 2.5% under 30 years until 35% in the eldest. PAH prevalence in the entire CHD population was 3.2%. Based on 3000 per million adult CHD patients in the general population, we can assume that PAH-CHD is present in 100 per million.

 

CONCLUSIONS - This new approach using a nationwide CHD population reports a PAH prevalence of 3.2% in CHD patients, and 100 per million in the general adult population. Especially in patients after shunt closure and the elderly, physicians should be aware of PAH-CHD, to provide optimal therapeutic and clinical care.

 

Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.